Lv41
520 积分 2025-01-15 加入
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
1个月前
已完结
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
1个月前
已完结
Ivonescimab in non-small cell lung cancer: harmonizing immunotherapy and anti-angiogenesis
1个月前
已完结
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
1个月前
已完结
International Trends in Esophageal Squamous Cell Carcinoma and Adenocarcinoma Incidence
2个月前
已完结
Update on Management of Squamous Cell Esophageal Cancer
2个月前
已完结
The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020
2个月前
已完结
皖公网安备34019202002308
